Author: Ana Aragon
Publisher:
ISBN: 9781905944163
Category : Occupational therapy
Languages : en
Pages : 76
Book Description
These practice guidelines draw upon the widest relevant knowledge and evidence available to describe and inform contemporary best practice occupational therapy for people with Parkinson's disease. They include practical examples of interventions to allow occupational therapists to apply new treatments to their practice.
Occupational Therapy for People with Parkinson's Disease
Author: Ana Aragon
Publisher:
ISBN: 9781905944163
Category : Occupational therapy
Languages : en
Pages : 76
Book Description
These practice guidelines draw upon the widest relevant knowledge and evidence available to describe and inform contemporary best practice occupational therapy for people with Parkinson's disease. They include practical examples of interventions to allow occupational therapists to apply new treatments to their practice.
Publisher:
ISBN: 9781905944163
Category : Occupational therapy
Languages : en
Pages : 76
Book Description
These practice guidelines draw upon the widest relevant knowledge and evidence available to describe and inform contemporary best practice occupational therapy for people with Parkinson's disease. They include practical examples of interventions to allow occupational therapists to apply new treatments to their practice.
Parkinson's Disease For Dummies
Author: Jo Horne
Publisher: John Wiley & Sons
ISBN: 1119893585
Category : Health & Fitness
Languages : en
Pages : 450
Book Description
Maintain a take-charge attitude and live your life to the fullest with Parkinson's Whether the diagnosis is yours or that of a loved one, Parkinson's Disease for Dummies contains everything you need to know about living with this disease. This book is an easy-to-understand, straightforward, and sometimes humorous guide that offers proven techniques for coping with daily issues, finding the right doctors, and providing care as the disease progresses. This user-friendly guide helps you navigate you through the important steps toward taking charge of your condition. You aren't alone—inside, you'll discover proven coping skills and first-hand advice, along with practical tools that will help you navigate the treatment journey. In classic, compassionate Dummies style, Parkinson's Disease For Dummies will answer all your questions, and guide you through the process of finding your own answers as well. Keep your mind sharp, stay in shape, and keep your stress under control Life a full and satisfying life after a Parkinson's diagnosis Get the most current information on Parkinson's medications and treatments Learn the best ways to support loved ones living with Parkinson's With updates on the latest in alternative treatments, dementia, and young onset PD, Parkinson's Disease for Dummies is here to show you how you can keep a positive attitude and lead an active, productive life.
Publisher: John Wiley & Sons
ISBN: 1119893585
Category : Health & Fitness
Languages : en
Pages : 450
Book Description
Maintain a take-charge attitude and live your life to the fullest with Parkinson's Whether the diagnosis is yours or that of a loved one, Parkinson's Disease for Dummies contains everything you need to know about living with this disease. This book is an easy-to-understand, straightforward, and sometimes humorous guide that offers proven techniques for coping with daily issues, finding the right doctors, and providing care as the disease progresses. This user-friendly guide helps you navigate you through the important steps toward taking charge of your condition. You aren't alone—inside, you'll discover proven coping skills and first-hand advice, along with practical tools that will help you navigate the treatment journey. In classic, compassionate Dummies style, Parkinson's Disease For Dummies will answer all your questions, and guide you through the process of finding your own answers as well. Keep your mind sharp, stay in shape, and keep your stress under control Life a full and satisfying life after a Parkinson's diagnosis Get the most current information on Parkinson's medications and treatments Learn the best ways to support loved ones living with Parkinson's With updates on the latest in alternative treatments, dementia, and young onset PD, Parkinson's Disease for Dummies is here to show you how you can keep a positive attitude and lead an active, productive life.
My Degeneration
Author: Peter Dunlap-Shohl
Publisher: Penn State Press
ISBN: 0271078952
Category : Comics & Graphic Novels
Languages : en
Pages : 110
Book Description
How does one deal with a diagnosis of Parkinson’s disease at the age of forty-three? My Degeneration, by former Anchorage Daily News staff cartoonist Peter Dunlap-Shohl, answers the question with humor and passion, recounting the author’s attempt to come to grips with the “malicious whimsy” of this chronic, progressive, and disabling disease. This graphic novel tracks Dunlap-Shohl’s journey through depression, the worsening symptoms of the disease, the juggling of medications and their side effects, the impact on relations with family and community, and the raft of mental and physical changes wrought by the malady. My Degeneration examines the current state of Parkinson’s care, including doctor/patient relations and the repercussions of a disease that, among other things, impairs movement, can rob patients of their ability to speak or write, degrades sufferers’ ability to deal with complexity, and interferes with the sense of balance. Readers learn what it’s like to undergo a dramatic, demanding, and audacious bit of high-tech brain surgery that can mysteriously restore much of a patient’s control over symptoms. But My Degeneration is more than a Parkinson’s memoir. Dunlap-Shohl gives the person newly diagnosed with Parkinson’s disease the information necessary to cope with it on a day-to-day basis. He chronicles the changes that life with the disease can bring to the way one sees the world and the way one is seen by the wider community. Dunlap-Shohl imparts a realistic basis for hope—hope not only to carry on, but to enjoy a decent quality of life.
Publisher: Penn State Press
ISBN: 0271078952
Category : Comics & Graphic Novels
Languages : en
Pages : 110
Book Description
How does one deal with a diagnosis of Parkinson’s disease at the age of forty-three? My Degeneration, by former Anchorage Daily News staff cartoonist Peter Dunlap-Shohl, answers the question with humor and passion, recounting the author’s attempt to come to grips with the “malicious whimsy” of this chronic, progressive, and disabling disease. This graphic novel tracks Dunlap-Shohl’s journey through depression, the worsening symptoms of the disease, the juggling of medications and their side effects, the impact on relations with family and community, and the raft of mental and physical changes wrought by the malady. My Degeneration examines the current state of Parkinson’s care, including doctor/patient relations and the repercussions of a disease that, among other things, impairs movement, can rob patients of their ability to speak or write, degrades sufferers’ ability to deal with complexity, and interferes with the sense of balance. Readers learn what it’s like to undergo a dramatic, demanding, and audacious bit of high-tech brain surgery that can mysteriously restore much of a patient’s control over symptoms. But My Degeneration is more than a Parkinson’s memoir. Dunlap-Shohl gives the person newly diagnosed with Parkinson’s disease the information necessary to cope with it on a day-to-day basis. He chronicles the changes that life with the disease can bring to the way one sees the world and the way one is seen by the wider community. Dunlap-Shohl imparts a realistic basis for hope—hope not only to carry on, but to enjoy a decent quality of life.
Rethinking Parkinson's Disease
Author: John C Coleman
Publisher: Hybrid Publishers
ISBN: 1925736474
Category : Health & Fitness
Languages : en
Pages : 417
Book Description
John Coleman was diagnosed with Parkinson's disease while studying to be a naturopath, and banished all the frustrating symptoms of this cruel condition from his body ... naturally! His new book equips those diagnosed with the knowledge needed to reverse their Parkinson's disease symptoms and even recover, using completely natural means. Rethinking Parkinson's Disease traces known pathways leading to a diagnosis of Parkinson's disease, together with strategies to reverse each pathway. It includes the best evidence from Western allopathic medicine and complementary/alternative medicine in discovering how and why people with Parkinson's develop symptoms, the diagnostic process, standard treatments and prognoses offered by expert practitioners, and ongoing research. The book presents strategies that have been shown, clinically or in research, to improve the health of people with Parkinson's, with the possibility of reversing symptoms. A major section of this work details strategies to create wellness, many available to patients at little or no cost. There are sections on symptom control, complementary medical treatments and therapies to avoid. The book is aimed primarily at people with Parkinson's, families and supporters, and may be used as a self-help book, including advice on building a team of supportive practitioners. There are also suggestions and advice for both Western allopathic medicine and complementary/alternative medicine practitioners to enhance their care of patients with a Parkinson's disease diagnosis, so it may be used as a handbook for practitioners wishing to move away from the standard conservative view of Parkinson's disease as an "incurable" disease.
Publisher: Hybrid Publishers
ISBN: 1925736474
Category : Health & Fitness
Languages : en
Pages : 417
Book Description
John Coleman was diagnosed with Parkinson's disease while studying to be a naturopath, and banished all the frustrating symptoms of this cruel condition from his body ... naturally! His new book equips those diagnosed with the knowledge needed to reverse their Parkinson's disease symptoms and even recover, using completely natural means. Rethinking Parkinson's Disease traces known pathways leading to a diagnosis of Parkinson's disease, together with strategies to reverse each pathway. It includes the best evidence from Western allopathic medicine and complementary/alternative medicine in discovering how and why people with Parkinson's develop symptoms, the diagnostic process, standard treatments and prognoses offered by expert practitioners, and ongoing research. The book presents strategies that have been shown, clinically or in research, to improve the health of people with Parkinson's, with the possibility of reversing symptoms. A major section of this work details strategies to create wellness, many available to patients at little or no cost. There are sections on symptom control, complementary medical treatments and therapies to avoid. The book is aimed primarily at people with Parkinson's, families and supporters, and may be used as a self-help book, including advice on building a team of supportive practitioners. There are also suggestions and advice for both Western allopathic medicine and complementary/alternative medicine practitioners to enhance their care of patients with a Parkinson's disease diagnosis, so it may be used as a handbook for practitioners wishing to move away from the standard conservative view of Parkinson's disease as an "incurable" disease.
Non-Motor Symptoms of Parkinson's Disease
Author: K. Ray Chaudhuri
Publisher: Oxford University Press, USA
ISBN: 0199684243
Category : Medical
Languages : en
Pages : 517
Book Description
Patients with Parkinson's disease (PD) are known to suffer from motor symptoms of the disease, but they also experience non-motor symptoms (NMS) that are often present before diagnosis or that inevitably emerge with disease progression. The motor symptoms of Parkinson's disease have been extensively researched, and effective clinical tools for their assessment and treatment have been developed and are readily available. In contrast, researchers have only recently begun to focus on the NMS of Parkinson's Disease, which are poorly recognized and inadequately treated by clinicians. The NMS of PD have a significant impact on patient quality of life and mortality and include neuropsychiatric, sleep-related, autonomic, gastrointestinal, and sensory symptoms. While some NMS can be improved with currently available treatments, others may be more refractory and will require research into novel (non-dopaminergic) drug therapies for the future. Edited by members of the UK Parkinson's Disease Non-Motor Group (PD-NMG) and with contributions from international experts, this new edition summarizes the current understanding of NMS symptoms in Parkinson's disease and points the way towards future research.
Publisher: Oxford University Press, USA
ISBN: 0199684243
Category : Medical
Languages : en
Pages : 517
Book Description
Patients with Parkinson's disease (PD) are known to suffer from motor symptoms of the disease, but they also experience non-motor symptoms (NMS) that are often present before diagnosis or that inevitably emerge with disease progression. The motor symptoms of Parkinson's disease have been extensively researched, and effective clinical tools for their assessment and treatment have been developed and are readily available. In contrast, researchers have only recently begun to focus on the NMS of Parkinson's Disease, which are poorly recognized and inadequately treated by clinicians. The NMS of PD have a significant impact on patient quality of life and mortality and include neuropsychiatric, sleep-related, autonomic, gastrointestinal, and sensory symptoms. While some NMS can be improved with currently available treatments, others may be more refractory and will require research into novel (non-dopaminergic) drug therapies for the future. Edited by members of the UK Parkinson's Disease Non-Motor Group (PD-NMG) and with contributions from international experts, this new edition summarizes the current understanding of NMS symptoms in Parkinson's disease and points the way towards future research.
Autonomic Dysfunction in Parkinson's Disease
Author: Cristian Falup-Pecurariu
Publisher: Academic Press
ISBN: 0323851231
Category : Technology & Engineering
Languages : en
Pages : 316
Book Description
Autonomic dysfunction is one of the most prevalent non-motor symptoms that occurs in Parkinson's disease. Autonomic Dysfunction in Parkinson's Disease provides up to date information on this important topic, which affects quality of life of these patients. This include a large number of domains: orthostatic hypotension, excessive sweating, dry eyes, constipation, weight loss, increased sensitivity to heat and cold, sexual dysfunction. - Provides comprehensive reviews on different topics of autonomic dysfunction in Parkinson's disease - Each chapter covers a specific autonomic symptom: classification, assessment, treatment - Presents the newest information on each autonomic symptom in Parkinson's disease
Publisher: Academic Press
ISBN: 0323851231
Category : Technology & Engineering
Languages : en
Pages : 316
Book Description
Autonomic dysfunction is one of the most prevalent non-motor symptoms that occurs in Parkinson's disease. Autonomic Dysfunction in Parkinson's Disease provides up to date information on this important topic, which affects quality of life of these patients. This include a large number of domains: orthostatic hypotension, excessive sweating, dry eyes, constipation, weight loss, increased sensitivity to heat and cold, sexual dysfunction. - Provides comprehensive reviews on different topics of autonomic dysfunction in Parkinson's disease - Each chapter covers a specific autonomic symptom: classification, assessment, treatment - Presents the newest information on each autonomic symptom in Parkinson's disease
Levodopa pharmacokinetics -from stomach to brain
Author: Maria Nord
Publisher: Linköping University Electronic Press
ISBN: 9176855570
Category :
Languages : sv
Pages : 81
Book Description
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.
Publisher: Linköping University Electronic Press
ISBN: 9176855570
Category :
Languages : sv
Pages : 81
Book Description
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.
Reverse Parkinson's Disease
Author: John Pepper
Publisher: Rosedog Press
ISBN: 9781434983534
Category : Biography & Autobiography
Languages : en
Pages : 193
Book Description
Publisher: Rosedog Press
ISBN: 9781434983534
Category : Biography & Autobiography
Languages : en
Pages : 193
Book Description
Parkinson's Disease
Author: National Institute of Neurological and Communicative Disorders and Stroke
Publisher:
ISBN:
Category : Parkinson's disease
Languages : en
Pages : 20
Book Description
Publisher:
ISBN:
Category : Parkinson's disease
Languages : en
Pages : 20
Book Description
An Essay on the Shaking Palsy
Author: James Parkinson
Publisher:
ISBN:
Category : Parkinson's disease
Languages : en
Pages : 86
Book Description
Publisher:
ISBN:
Category : Parkinson's disease
Languages : en
Pages : 86
Book Description